Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 27 - Drugs for disorders of the senses
Patents for A61P 27 - Drugs for disorders of the senses (53,017)
11/2003
11/06/2003WO2003091259A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003WO2003091258A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003091256A1 PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
11/06/2003WO2003091247A2 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003WO2003091245A1 4,4-disubstituted piperidine derivatives having ccr3 antagonism
11/06/2003WO2003091242A1 Novel thiol derivative, process for producing the same and use thereof
11/06/2003WO2003091241A1 3, 4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003WO2003091236A1 Imidazolinylmethyl aralkylsulfonamides
11/06/2003WO2003091227A1 Tachykinin receptor antagonists
11/06/2003WO2003091215A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo’ b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003WO2003091214A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo
11/06/2003WO2003091204A1 Phenethanolamine derivatives
11/06/2003WO2003090805A1 Process for production of hydrogel material enhanced in the intake of drugs and permitting sustained release of drugs
11/06/2003WO2003090767A1 An injection made from ixeris sonchifolia for treatment of cardio-cerebral vascular disease and fundus diseases and method of producing thereof
11/06/2003WO2003090752A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003WO2003090751A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003WO2003090748A1 Use of compounds having ccr antagonism
11/06/2003WO2003090712A2 Compositions for treating hyperemia
11/06/2003WO2003090671A2 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003WO2003090662A2 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003WO2003059193A3 Use of nanoparticles as carriers for biocides in ophthalmic compositions
11/06/2003WO2003057166A3 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003WO2003055983A3 Targeted retrograde gene delivery to motor neurons
11/06/2003WO2003035626A3 Azole derivatives and pharmaceutical compositions containing them
11/06/2003WO2003035005A3 Heteroindanes: a new class of potent cannabimimetic ligands
11/06/2003WO2003031939A3 Protein modification and maintenance molecules
11/06/2003WO2003027263A3 Proteins associated with cell growth, differentiation, and death
11/06/2003WO2003018049A3 Use of milk serum apoproteins in the prophylaxis or treatment of microbial or viral infection
11/06/2003WO2002076979A8 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
11/06/2003US20030208084 Sulfonamides and derivatives thereof that modulate the activity of endothelin
11/06/2003US20030208067 Inhibitors of protein kinase for the treatment of disease
11/06/2003US20030208058 B7-like polypeptides and polynucleotides
11/06/2003US20030207943 Administering dopamine, serotonin, and norepinephrine reuptake inhibitor (sibutramine) for treatment of neuropsychiatric disorders
11/06/2003US20030207941 Method of treating vascular endothelial growth factor mediated vascular disorders
11/06/2003US20030207937 Such as ethyl-2,2-4,4-tetramethyl-chroman-6-carboxylate; for retinoid-treatable conditions
11/06/2003US20030207931 Use of 3-(2-ethylphenyl)-5-(3-methoxyphenyl)-1h-1,2,4-triazole for the treatment of autoimmune diseases
11/06/2003US20030207930 Valsartan salts
11/06/2003US20030207925 Methods of treatment with selective EP4 receptor agonists
11/06/2003US20030207919 For treating, preventing, reducing inflammation, pain, fever,gastrointestinal disorders; decreasing gastrointestinal, renal and other toxicities resulting from use of nonsteroidal antiinflammatory drugs; multiplicity of compounds
11/06/2003US20030207913 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
11/06/2003US20030207906 Chemical compounds
11/06/2003US20030207881 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
11/06/2003US20030207879 Preferential G protein coupled receptor antagonists, such as 8-(3-amino-1-methyl-1H-pyrazol-5-yl)-1,3-dipropyl-3,7-dihydro -1H-purine-2,6-dione, used for prophylaxis of asthma, autoimmune diseases or retinopathy
11/06/2003US20030207878 Drugs used as angiogenesis inhibitors, vascular permeability or endothelial growth factor antagonists, for prophylaxis of cancer, diabetes, psoriasis, arthritis, autoimmune diseases, inflammation or scar formation
11/06/2003US20030207870 Aryl ureas with angiogenisis inhibiting activity
11/06/2003US20030207867 Method of treating a male or female animal in the treatment of a condition where inhibition of a cGMP-specific PDE is of a therapeutic benefit comprising treating said animal with an effective amount of a pharmaceutical composition with carriers
11/06/2003US20030207846 Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin
11/06/2003US20030207450 Derived from the neuroretina of the eye ex vivo and in vivo
11/06/2003US20030207434 Phosphodiesterases
11/06/2003US20030207318 Kinesin-like motor protein
11/06/2003US20030207309 Diagnostics and therapeutics for macular degeneration-related disorders
11/06/2003US20030206970 Ophthalmic compositions containing galactomannan polymers and borate
11/06/2003US20030206956 Topical treatment of prevention of ocular infections
11/06/2003US20030206955 Oil-in-water; nonionic and/or anionic amphiphilic lipid; anionic polymer which contains at least one hydrophobic chain; weight ratio of the amount of oily phase to the amount of amphiphilic lipid ranges from 1.2 to 10.
11/06/2003US20030206898 Use of anti-TNFalpha antibodies and another drug
11/06/2003US20030206861 Uses of diterpenoid triepoxides as an antiproliferative agent
11/06/2003CA2487245A1 An injection made from ixeris sonchifolia hance for treatment of cardio-cerebral vascular diseases and fundus diseases and method of producing thereof
11/06/2003CA2484067A1 Triaryl-oxy-aryloxy-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/06/2003CA2483636A1 3,4-dihydroquinolin-2(1h)-one compounds as nr2b receptor antagonists
11/06/2003CA2483515A1 Novel thiol derivative, method for producing the same and use thereof
11/06/2003CA2483504A1 4,4-(disubstituted)piperidine derivatives with ccr3 antagonism
11/06/2003CA2483500A1 Pyrimidine-2, 4, 6-trione metallo-proteinase inhibitors
11/06/2003CA2483314A1 Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
11/06/2003CA2483306A1 Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
11/06/2003CA2483265A1 Growth factor delivery system for the healing of wounds and the prevention of inflammation and disease
11/06/2003CA2483253A1 Use of compounds having ccr antagonism
11/06/2003CA2483091A1 3-substituted amino-1h-indole-2-carboxylic acid and 3-substituted amino-benzo' b! thiophene-2-carboxylic acid derivatives as interieukin-4 gene expression inhibitors
11/06/2003CA2483075A1 Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
11/06/2003CA2483007A1 A dna enzyme to inhibit plasminogen activator inhibitor-1
11/06/2003CA2480268A1 Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
11/06/2003CA2480092A1 N-substituted-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors
11/05/2003EP1358883A1 Re-epithelializing pharmaceutical compositions containing xanthan gum
11/05/2003EP1358206A2 Peptide-based compounds
11/05/2003EP1358186A1 Laulimalide derivatives
11/05/2003EP1358184A1 Substituted alkylamine derivatives and methods of use
11/05/2003EP1358182A1 Diazocine derivatives and their use as tryptase inhibitors
11/05/2003EP1358178A2 Sulfonamide lactam inhibitors of factor xa
11/05/2003EP1358161A2 N-pyridyl carboxamide derivatives and pharmaceutical compositions containing them
11/05/2003EP1358160A1 Aminal diones as potassium channel openers
11/05/2003EP1358153A1 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1357930A2 Histidine-rich glycoprotein
11/05/2003EP1357925A2 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use
11/05/2003EP1357915A2 PHARMACEUTICAL FORMULATION COMPRISING PYRAZOLO 4,3-d]PYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS OR THIENOPYRIMIDINES AND ENDOTHELIN RECEPTOR ANTAGONISTS
11/05/2003EP1357912A2 Photodynamic therapy of occult choroidal neovascularization linked to age-related macular degeneration
11/05/2003EP1357908A2 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
11/05/2003EP1357904A2 Use of pyrazolo 4,3-d]pyrimidines
11/05/2003EP1357855A2 Ophthalmic compositions for treating ocular hypertension
11/05/2003EP1268480B1 8-quinolinxanthine and 8-isoquinolinxanthine derivatives as pde 5 inhibitors
11/05/2003EP1220858B1 Oxazinoquinolones useful for the treatment of viral infections
11/05/2003EP1107973B1 NOVEL THIENO[2,3-d]PYRIMIDINEDIONES, PROCESS FOR THEIR PREPARATION AND USE THEREOF IN THERAPY
11/05/2003EP1054857B1 Biaryl-acetic acid derivatives and their use as cox-2 inhibitors
11/05/2003CN1454210A 嘧啶衍生物 Pyrimidine derivatives
11/05/2003CN1454091A Immunostimulatory nucleic acids
11/05/2003CN1453025A Plant leaven with hot and fragrant smell of propylene sulfide and its prepn and use
11/05/2003CN1453019A Chinese medicine for treating eye diseases of middle-aged and old people and its prepn
11/05/2003CN1452955A Eyesight improving prepn
11/05/2003CN1126568C Adjuvant used in vaccine
11/05/2003CN1126565C External application traditional Chinese medicine prepn. for treating viral deaf
11/04/2003US6642267 Side effect reduction over opioid analgesics; analgesic and/or anxiolytic action
11/04/2003US6642256 Brain disorders, psychological disorders, antiischemic agents, central nervous system disorders
1 ... 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 ... 531